Contact Us
  • Choose License Type

Global Wound Debridement Products Market, by Product Type (Hydrosurgical Debridement Devices, Low Frequency Ultrasound Devices, Surgical Wound Debridement Devices, Mechanical Debridement Pads, Traditional Wound Debridement Devices, and Larval Therapy), by Application (Chronic Ulcers, Surgical Wounds, Traumatic Wounds, and Burn Cases), by End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics, Nursing Facilities, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is expected to be valued at US$ 561.31million in 2019, and is expected to exhibit a CAGR of 9.2% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are focused on launching new and advanced wound debridement products in order to expand their product offerings. For instance, in January 2018, Exsurco Medical, Inc. launched Amalgatome SD, a wound debridement and skin grafting medical device for use in burn and trauma centers. The Amalgatome SD contains the excision ring design along with machined bearings and gear teeth which provide sharpness and precision to the surgical steel edge during skin grafting and wound debridement procedures.

Similarly, in February 2016, Angelini S.p.a., an Italian pharmaceutical company, launched an acid-oxidizing solution which contains hypochlorous acid in the Italian market. The hypochlorous acid-oxidizing solution is indicated for the debridement, cleansing, irrigation and moisturizing of chronic and acute ulcers.

Browse 27 Market Data Tables and 25 Figures spread through 170 Pages and in-depth TOC on “Wound Debridement Products Market”- Global Forecast to 2027, by Product Type (Hydrosurgical Debridement Devices, Low Frequency Ultrasound Devices, Surgical Wound Debridement Devices, Mechanical Debridement Pads, Traditional Wound Debridement Devices, and Larval Therapy), by Application (Chronic Ulcers, Surgical Wounds, Traumatic Wounds, and Burn Cases), by End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics, Nursing Facilities, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global wound debridement products market, click the link below:

https://www.coherentmarketinsights.com/market-insight/wound-debridement-products-market-3784

Major players operating in wound debridement products market have been enhancing their research and development activities in order to expand their product portfolio which is expected to boost the market growth over the forecast period. For instance, in July 2019, MediWound Ltd., announced the U.S. clinical development plan for EscharEx, a biological drug for the debridement of chronic wounds. MediWound Ltd., will be initiating a phase 2 clinical trial in the fourth quarter of 2019, to assess the safety and efficacy of EscharEx for the enzymatic and autolytic debridement of chronic wounds.  

Key Takeaways of the Global Wound Debridement Products Market:

  • The global wound debridement products market is expected to exhibit a CAGR of 9.2% over the forecast period, owing to increased product launches and approvals and increasing incidence of injuries. According to the Centers for Disease Control and Prevention (CDC), around 273,272 children were treated for nonfatal traumatic brain injuries (TBIs) related to sports and recreation, in the U.S. emergency departments, in 2016.
  • Among product type, the low frequency ultrasound devices segment held a higher market share in 2018 owing to launches of new wound debridement technologies. For instance, April 2016, Misonix, Inc., an ultrasonic surgical device company, announced the launch of SonicVac, designed to remove the debris and infected tissues combined with ultrasoci wound debridement.
  • Among application, the chronic ulcers segment held a higher market share in 2018 owing to the rising prevalence of chronic ulcers. According to American College of Physicians, 2017, lifetime incidence of foot ulcers in diabetic patients ranges from 19% to 34%.
  • Companies operating in the global wound debridement products market include Smith & Nephew plc., Lohmann & Rauscher International GmbH & Co. KG (L&R Group), Medaxis, DeRoyal Industries, Inc., Monarch Labs, Arobella Medical, LLC, Zimmer Biomet, Misonix, Inc., Bactiguard AB, MediWound Ltd., and Söring GmbH.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner